Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting

Ruiting Guo; Wenyi Lu; Yi Zhang; Xinping Cao; Xin Jin; Mingfeng Zhao

doi:10.3389/fimmu.2022.839097

Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting

Front Immunol. 2022 Mar 7:13:839097. doi: 10.3389/fimmu.2022.839097. eCollection 2022.

Authors

Ruiting Guo¹, Wenyi Lu², Yi Zhang¹, Xinping Cao¹, Xin Jin², Mingfeng Zhao²

Affiliations

¹ First Center Clinic College of Tianjin Medical University, Tianjin, China.
² Department of Hematology, Tianjin First Central Hospital, Tianjin, China.

Abstract

With the gradual improvement of treatment regimens, the survival time of multiple myeloma (MM) patients has been significantly prolonged. Even so, MM is still a nightmare with an inferior prognosis. B-cell maturation antigen (BCMA) is highly expressed on the surface of malignant myeloma cells. For the past few years, significant progress has been made in various BCMA-targeted immunotherapies for treating patients with RRMM, including anti-BCMA mAbs, antibody-drug conjugates, bispecific T-cell engagers, and BCMA-targeted adoptive cell therapy like chimeric antigen receptor (CAR)-T cell. The 63rd annual meeting of the American Society of Hematology updated some information about the application of BCMA in MM. This review summarizes part of the related points presented at this conference.

Keywords: B-cell maturation antigen; CAR-T cell therapy; antibody-drug conjugates; bispecific T-cell engagers; immunotherapy; multiple myeloma.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

B-Cell Maturation Antigen
Humans
Immunoconjugates* / therapeutic use
Immunotherapy, Adoptive
Multiple Myeloma* / drug therapy
Receptors, Chimeric Antigen* / therapeutic use

Substances

B-Cell Maturation Antigen
Immunoconjugates
Receptors, Chimeric Antigen